Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | LPO | P22079 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19090065 | 1.00 | CCNE1 (0.35) | CCNE1CDK2LPOL3MBTL1F10 | |
| SCHEMBL19090066 | 1.00 | CCNE1 (0.35) | CCNE1CDK2LPOL3MBTL1F10 | |
| SCHEMBL27217166 | 0.86 | CCNE1 (0.41) | CCNE1CDK2LPOL3MBTL1F10 | |
| SCHEMBL12903263 | 0.80 | CCNE1 (0.46) | CCNE1CDK2LPOL3MBTL1F10 | |
| SCHEMBL19090068 | 0.80 | CCNE1 (0.33) | CCNE1CDK2LPOL3MBTL1F10 | |
| SCHEMBL19090069 | 0.80 | CCNE1 (0.33) | CCNE1CDK2LPOL3MBTL1F10 | |
| SCHEMBL21998513 | 0.80 | CCNE1 (0.33) | CCNE1CDK2LPOL3MBTL1 | |
| SCHEMBL19079539 | 0.80 | CCNE1 (0.33) | CCNE1CDK2LPOL3MBTL1 | |
| SCHEMBL19079538 | 0.80 | CCNE1 (0.33) | CCNE1CDK2LPOL3MBTL1 | |
| SCHEMBL27217134 | 0.79 | LPO (0.38) | CCNE1CDK2LPOL3MBTL1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980875-B2 | Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-03-17 | — | — | US | disclosed |
| US-20130338128-A1 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-12-19 | — | — | US | disclosed |
| US-8481522-B2 | Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-07-09 | — | — | US | disclosed |
| EP-2268652-B1 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2012-12-19 | — | — | EP | disclosed |
| US-20110172199-A1 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-14 | — | — | US | disclosed |
| EP-2268652-A2 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009118475-A2 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338128-A1 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SCO2, C3AR1, IDH1 | CCNE1 401/4885CDK2 567/4885LPO 962/4885 |
| US-20110172199-A1 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SCO2, C3AR1, IDH1 | CCNE1 401/4885CDK2 567/4885LPO 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.